EntityQ7825683· pop 17· linked from 448 articles

tedizolid

Tedizolid, sold under the brand name Sivextro (by Merck) is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).

Key facts

Drug.F: 1
Drug.N: 6
Drug.O: 3
Drug.Verifiedfields: changed
Drug.verifiedrevid: 470611892
Drug.image: Tedizolid.svg
Drug.image_class: skin-invert-image
Drug.image2: Tedizolid 3D molecule.png
Drug.image_class2: bg-transparent
Drug.tradename: Sivextro
Drug.MedlinePlus: a614038
Drug.DailyMedID: Tedizolid
Drug.routes_of_administration: By mouth, intravenous
Drug.ATC_prefix: J01
Drug.ATC_suffix: XX11
Drug.legal_CA: Rx-only
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only

via Wikipedia infobox

Research

545 papers

Tedizolid.2006
Tedizolid.2012
Pharmacokinetics and Pharmacodynamics of Tedizolid.Clinical pharmacokinetics · 2022
Tedizolid for osteoarticular infections: Evaluation of the published evidence.European journal of pharmacology · 2025
Tedizolid: new data and experiences for clinical practice.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021

via PubMed

Article

7 sections

Contents

Medical uses
Mechanism of action
Pharmacokinetic/pharmacodynamic (PK/PD) properties
Clinical trials
Adverse effects
References
External links

{{Infobox drug | Verifiedfields = changed | verifiedrevid = 470611892 | image = Tedizolid.svg | image_class = skin-invert-image | alt = | image2 = Tedizolid 3D molecule.png | image_class2 = bg-transparent | alt2 =